Switch View
© Globe Newswire
04.11.2025
ISIN: US23284F1057
CytomX Therapeutics Inc
CTMX
LISTED
NASDAQ
CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
News Preview
- CX-801 (PROBODY® interferon alpha-2b) Phase 1 data demonstrate activation of tumor-selective interferon signaling in patients with advanced melanoma -...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US53216B1044
LifeMD, Inc.
LFMD
LISTED
NASDAQ
LifeMD Divests Majority Interest in WorkSimpli Software, Positioning Company as a Pure-Play Virtual Care and Pharmacy Platform
News Preview
Transaction Values WorkSimpli at $65 Million Enterprise Value; Supports LifeMD’s Strategic Focus on Scaling its Virtual Care and Pharmacy Businesses Transaction Values WorkSimpli at $65 Million Enterprise Value; Supports LifeMD’s Strategic Focus on Scaling its Virtual Care and Pharmacy Businesses...
Themefolio
Profiler
Peergroup
© EQS Newswire
04.11.2025
ISIN: DE0006595101
Mediclin AG
MED
LISTED
XETR
Geschäftsentwicklung im Rahmen der Erwartungen
News Preview
Offenburg, 4. November 2025
MEDICLIN auf Kurs: Geschäftsentwicklung im Rahmen der Erwartungen
Konzernbetriebsergebnis beträgt 48,9 Mio. Euro (9M 2024: 34,5 Mio. Euro)
Konzernumsatz liegt bei 586,9 Mio. Euro (9M 2024: 558,2 Mio. Euro)
Gesamtauslastung mit 86,8 % stabil
O......
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© EQS Newswire
04.11.2025
ISIN: DE0006595101
Mediclin AG
MED
LISTED
XETR
business development in line with expectations
News Preview
Offenburg, 4 November 2025
MEDICLIN on track: business development in line with expectations
Group operating result amounts to EUR 48.9 million (9M 2024: EUR 34.5 million)
Consolidated group sales amounts to EUR 586.9 million (9M 2024: EUR 558.2 million)
Overall capacit......
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
04.11.2025
ISIN: GB00BN455J50
Worldwide Healthcare Trust PLC
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Net Asset Value(s)
News Preview
WORLDWIDE HEALTHCARE TRUST PLC
LEI: 5493003...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: KYG2545C1042
Crescent Biopharma, Inc.
CBIO
LISTED
NASDAQ
Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
News Preview
CR-001 Demonstrated Cooperative Pharmacology and Robust Anti-Tumor Activity IND Submission for CR-001 On Track for Fourth Quarter of 2025 to Support Initiation of Global Phase 1 Trial in Patients with Solid Tumors...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US71902K1051
CERo Therapeutics Holdings, Inc.
CERO
LISTED
NASDAQ
CERo Therapeutics to Present Data at the Society for Immunotherapy of Cancer Conference Highlighting Lead Compound CER-1236 Sustained Cell Expansion and Cytokine Response
News Preview
Newly released preclinical data to be presented in a poster on November 8, 2025...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US00901B1052
AIM ImmunoTech Inc.
AIMI
LISTED
OTC
AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
News Preview
OCALA, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that data from the completed Phase 2 cisplatin-resistant advanced recurrent ovarian cancer clinical study utilizing Ampligen® (rintatolimod) was accepted in a late-breaking abstract at the 40th Annual SITC Meeting being...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US69404D1081
Pacific Biosciences of California Inc
PACB
LISTED
NASDAQ
PacBio Supports Berry Genomics in Achieving First Regulatory Approval for Clinical Long-Read Sequencing in China
News Preview
NMPA approval on the Sequel II CNDx system enables clinicians in China to harness PacBio HiFi sequencing for challenging conditions, with initial offering for thalassemia NMPA approval on the Sequel II CNDx system enables clinicians in China to harness PacBio HiFi sequencing for challenging conditions, with initial offering for thalassemia...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US23918K1088
DaVita Inc
DVA
LISTED
NYSE
DaVita Marks 25 Years of Innovation with Breakthrough Kidney Care Research at ASN Kidney Week 2025
News Preview
Six
new studies from DaVita Clinical Research spotlight improved outcomes with GLP-1 use, advancements in treatments, transplant access and end-of-life care
DENVER and HOUSTON, Nov. 4, 2025 /PRNewswire/ -- DaVita, a steadfast leader in kidney...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US2521311074
Dexcom Inc
DXCM
LISTED
NASDAQ
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit
News Preview
NEW YORK, Nov. 4, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between July 26, 2024 and September 17, 2025, both dates inclusive (the "Class Period"). A class action...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US15135B1017
Centene Corp
CNC
LISTED
NYSE
Delaware First Health and the Centene Foundation Announce Grant Program Recipients
News Preview
Grants awarded to Delaware community-based organizations tackling housing insecurity and transportation barriers
NEWARK, Del., Nov. 4, 2025 /PRNewswire/ -- Delaware First Health, a leading Medicaid managed care organization in Delaware, and the Centene Foundatio...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
04.11.2025
ISIN: US98420P3082
Xtant Medical Holdings, Inc.
XTNT
LISTED
XASE
Xtant Medical to Announce Third Quarter 2025 Financial Results on November 11, 2025
News Preview
BELGRADE, Mont., Nov. 4, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today announced that it will release its financial results for the third quarter end...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US87583X1090
Tango Therapeutics Inc
TNGX
LISTED
NASDAQ
Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights
News Preview
– Data update from vopimetostat (TNG462) showed 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months– ...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US20454B1044
Compass Therapeutics Inc.
CMPX
LISTED
NASDAQ
Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
News Preview
BOSTON, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced its poster presentation at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place November 5-9, 2025, in Nat...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US1374041093
Candel Therapeutics, Inc.
CADL
LISTED
NASDAQ
Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors
News Preview
NEEDHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company developing multimodal biological immunotherapies to help patients fight cancer, today announced it will deliver three presentations at the Society for Immunotherapy of Cancer (SITC) 40th An...
Themefolio
Profiler
Peergroup
© Newsfile
04.11.2025
ISIN: US29415V1098
Envoy Medical, Inc.
COCH
LISTED
NASDAQ
Envoy Medical Announces First Three Patients Enrolled in Final Stage of Acclaim(R) Cochlear Implant Pivotal Clinical Trial
News Preview
Rapid patient enrollment underscores strong market interest and reinforces commercialization opportunity for fully implanted cochlear implantsWhite Bear Lake, Minnesota--(Newsfile Corp. - November 4, 2025) - Envoy Medical, Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions,...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US1407553072
Tvardi Therapeutics Inc
TVRD
LISTED
NASDAQ
Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
News Preview
Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the Company’s Management will present at the Jefferies Global Healthcare Conference in London, UK, on Tuesday, Nov...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US81728J1097
Sensus Healthcare, Inc.
SRTS
LISTED
NASDAQ
CMS Establishes Coding Validating Sensus SRT for Treating Non-Melanoma Skin Cancer
News Preview
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces that the Centers for Medicare & Medicaid Services (CMS) has published a distinct set of treatment codes specific to the...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US02043Q1076
Alnylam Pharmaceuticals Inc
ALNY
LISTED
NASDAQ
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences:
UBS Global Healthcare Conference on Monday, November 10, 2025, at 10:15 AM ET in Palm Beach Gardens, Florida
Jefferies Global Healthcare Conference o...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US24661P8077
Delcath Systems, Inc.
DCTH
LISTED
NASDAQ
Delcath Systems Reports Third Quarter 2025 Results and Business Highlights
News Preview
Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced financial results and business highlights for the third quarter ended September 30, 2025.
Third Quarter 2025 Financial Results
Total revenue of $20.6 million, com...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US22407B1089
Coya Therapeutics, Inc.
COYA
LISTED
NASDAQ
Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo
News Preview
Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, today announced results of an in vivo animal study designed to evaluate the effects of COYA 303 (LD IL-2 and GLP-1RA investigational proprietary biologic combination) i...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US81663L2007
GeneDx Holdings Corp
WGS
LISTED
NASDAQ
GeneDx to Participate in Upcoming Investor Conferences
News Preview
GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:
Stifel 2025 Healthcare Conference
New York, New York
Fireside Chat: Wednesday, November 12 at 2:00 p.m. ET
Jefferies Global Healthcare Conference
Lo...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US80706P1030
Scholar Rock Holding Corp
SRRK
LISTED
NASDAQ
Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference
News Preview
Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that ma...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US3741631036
Geron Corp
GERN
LISTED
NASDAQ
Geron Corporation to Present at Upcoming Investor Conferences
News Preview
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that Harout Semerjian, Chief Executive Officer, is scheduled to present at the following investor conferences:
Stifel 2025 Healthcare Conference
Fireside chat on Tuesday, November 11 at 11...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US48301N1046
Kairos Pharma Ltd
KAPA
LISTED
XASE
Kairos Pharma Provides Shareholder Update
News Preview
Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, provides an overview of key 2025 milestones and outlook into 2026 in a Letter to Shareholders from CEO John Yu, M.D. presented below.
To our valued Kairos Pharma Shareholders,
This year, Kairos has been focused on exe...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US90184D1000
Twist Bioscience Corp
TWST
LISTED
NASDAQ
Twist Bioscience to Present at 7th Annual Wolfe Research Healthcare Conference
News Preview
Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience and Adam Laponis, CFO of Twist, will participate in a fireside chat at the at 7th Annual Wolfe Research Healthcare Conference on Monday, November 17, 2025 at 3:20 pm Eastern...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US2560861096
DocGo Inc
DCGO
LISTED
NASDAQ
DocGo Announces Upcoming Launch of Longitudinal Care Services for Major California Health Plan
News Preview
DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health and medical transportation services, today announced plans to launch Longitudinal Care Services in partnership with a California-based insurance provider. Leveraging the Company’s primary care capabilities, this program will provide prevent...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US00507W1071
Actinium Pharmaceuticals Inc
ATNM
LISTED
XASE
Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications
News Preview
- New preclinical data to show anti-tumor activity of ATNM-400 in hormone-resistant and HER2-resistant breast cancer, addressing the need for new treatment options beyond tamoxifen and trastuzumab
- ATNM-400 demonstrates efficacy across prostate cancer, non-small cell lung cance...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US04301G1022
Artelo Biosciences, Inc.
ARTL
LISTED
NASDAQ
Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer
News Preview
Highlights Broad Development Potential of Proprietary Portfolio Targeting FABPs Highlights Broad Development Potential of Proprietary Portfolio Targeting FABPs...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US8723811084
TELA Bio Inc
TELA
LISTED
NASDAQ
TELA Bio to Announce Third Quarter 2025 Financial Results
News Preview
MALVERN, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report third quarter 2025 financial results on Thursday, November 13, 2025. TELA Bio’s management will...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US01626L1052
Aligos Therapeutics, Inc.
ALGS
LISTED
NASDAQ
Aligos Therapeutics to Present at Upcoming Investor Conferences
News Preview
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at two upcoming investor conferences....
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US04280A1007
Arrowhead Pharmaceuticals Inc
ARWR
LISTED
NASDAQ
Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences
News Preview
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:
American Heart Association (AHA) Scientific Sessions 2025 – November 7-10, 2025
Title: Rationale and Design: Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Zodasiran in Adoles...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US4131971040
Harmony Biosciences Holdings Inc
HRMY
LISTED
NASDAQ
Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M
News Preview
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced earnings of $239.5M for Q3 2025, representing 29% year-over-year revenue growth for WAKIX®. These results were driven by the highest ever increase in average number of patients of approximately 500 for the quarter, accelerating the trajectory toward blockbuster status for WAKIX in n...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US67080T1088
Nuvectis Pharma Inc
NVCT
LISTED
NASDAQ
CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
News Preview
FORT LEE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on November 4, 2025 at 07:30 ET by Nuvectis Pharma, Inc. (NASDAQ: NVCT), the tables were not included. The tables have been added and the corrected release follows:...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US9224751084
Veeva Systems Inc
VEEV
LISTED
NYSE
Veeva Basics Adopted by More Than 100 Emerging Biotechs to Simplify and Standardize Operations
News Preview
New applications include Veeva LIMS Basics and PromoMats Basics to drive speed and growth
PLEASANTON, Calif., Nov. 4, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that more than 100 biotechs have selected Veeva Basics to advance operations across clinical, regulatory, and qualit...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US9224751084
Veeva Systems Inc
VEEV
LISTED
NYSE
Veeva Basics Adopted by More Than 100 Emerging Biotechs to Simplify and Standardize Operations
News Preview
New applications include Veeva LIMS Basics and PromoMats Basics to drive speed and growth
BARCELONA, Spain, Nov. 4, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that more than 100 biotechs have selected Veeva Basics to advance operations acros...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US15135B1017
Centene Corp
CNC
LISTED
NYSE
Ambetter from WellCare of Kentucky Offers Health Insurance in Kentucky in 2026
News Preview
During open enrollment, starting Nov. 1, residents can access affordable Ambetter from WellCare of Kentucky plans in 108 counties.
LOUISVILLE, Ky., Nov. 4, 2025 /PRNewswire/ -- Ambetter from WellCare of Kentucky, a product offered by a Centene Corporation (NYSE:...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US4277461020
Heron Therapeutics Inc
HRTX
LISTED
NASDAQ
Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress
News Preview
CARY, N.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced financial results for the three and nine months ended September 30, 2025 and recent corporate updates....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US30068X1037
Exagen Inc
XGN
LISTED
NASDAQ
Exagen Inc. Reports Strong Q3 2025 Results
News Preview
CARLSBAD, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2025, and recent corporate updates....
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US0223071020
Alumis, Inc.
ALMS
LISTED
NASDAQ
Alumis to Participate in Upcoming November Investor Conferences
News Preview
Alumis to participate in two upcoming November investor conferences: Guggenheim’s 2nd Annual Healthcare Innovation Conf and the Stifel 2025 Healthcare Conf...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US3207031010
Calidi Biotherapeutics, Inc.
CLDI
LISTED
XASE
Calidi Biotherapeutics Announces Investor Event to be Held on Friday, November 7th at the 2025 SITC Annual Meeting
News Preview
SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, today announced that it will hold an investor event at the Society of Immunotherapy for Cancer (SITC)...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US12674W1099
Cabaletta Bio Inc
CABA
LISTED
NASDAQ
Cabaletta Bio to Participate in Upcoming Investor Conferences in November and December
News Preview
PHILADELPHIA, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in the following upcoming investor...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US03969K1088
Arcutis Biotherapeutics Inc
ARQT
LISTED
NASDAQ
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis in American Journal of Clinical Dermatology
News Preview
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data of ZORYVE® (roflumilast) Foam 0.3% in Individuals with Seborrheic Dermatitis...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US0396971071
Ardelyx Inc
ARDX
LISTED
NASDAQ
Ardelyx President and Chief Executive Officer Mike Raab to Participate in the Wedbush Rewind American Society of Nephrology 2025 Investor Conference
News Preview
WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that President and CEO, Mike Raab will participate in a fireside chat at the Wedbu...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.11.2025
ISIN: US29664W1053
Esperion Therapeutics Inc
ESPR
LISTED
NASDAQ
Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer
News Preview
– Brings Extensive Executive Leadership Driving Commercial Strategies That Enhance Sales and Marketing Performance –...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US86627T1088
Summit Therapeutics Inc
SMMT
LISTED
NASDAQ
Summit Therapeutics to Present at Upcoming Investor Conferences
News Preview
Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at four upcoming investor conferences during the remainder of this year. Members of the Summit leadership team will participate in fireside chats and individual investor meetings at the following conferences:
UBS Glo...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US91307C1027
United Therapeutics Corp
UTHR
LISTED
NASDAQ
United Therapeutics Corporation to Present at Upcoming Investor Conferences
News Preview
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that company executives will provide an overview and update on the company during fireside chat sessions at two upcoming investor conferences.
Patrick Poisson, Executive Vice President, Strategic Development, will present at the UBS Global Healthcare Co...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US00653Q1022
Adapthealth Corp
AHCO
LISTED
NASDAQ
AdaptHealth Corp. Announces Third Quarter 2025 Results
News Preview
AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today financial results for the third quarter ended September 30, 2025.
Third Quarter Business Highlights
Signed anot...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US29251M1062
Enanta Pharmaceuticals Inc
ENTA
LISTED
NASDAQ
Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences
News Preview
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in the following investor conferences in November and December.
Jefferies London Global Healthcare Confer...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US68752M1080
Orthofix Medical Inc
OFIX
LISTED
NASDAQ
Orthofix Reports Third Quarter 2025 Financial Results
News Preview
Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the third quarter ended September 30, 2025, narrowed its full-year 2025 net sales guidance while maintaining the midpoint, and raised the low end of its adjusted EBITDA guidance. All pro forma measures contained within this re...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: GG00BMF1JR16
Genius Sports Limited
GENI
LISTED
NYSE
Genius Sports Reports 38% Group Revenue Growth and Raises Full-Year 2025 Group Revenue and Adj. EBITDA Guidance, Driven by Strengthening Media Product
News Preview
Genius Sports Limited (NYSE:GENI) (“Genius Sports,” "Genius" or the “Group”), the official data, technology and broadcast partner that powers the global ecosystem connecting sports, betting and media, today announced financial results for its fiscal third quarter ended September 30, 2025.
“Our growth this quarter reflects our unique ability to c...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US30063P1057
Exact Sciences Corp
EXAS
LISTED
NASDAQ
Exact Sciences to Participate in November Investor Conference
News Preview
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conference and invited investors to participate by webcast.
Jefferies London Healthcare Conference, London
Fireside chat on Tuesday, November 18, 2025 at 7:30 a.m. ET (12:30...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US98978V1035
Zoetis Inc
ZTS
LISTED
NYSE
Zoetis Announces Third Quarter 2025 Results
News Preview
Zoetis Inc. (NYSE:ZTS) today reported its financial results for the third quarter of 2025.
The company reported revenue of $2.4 billion for the third quarter of 2025, an increase of 1% compared with the third quarter of 2024. On an organic operational1 basis, revenue for the third quarter of 2025 increased 4% compared with the third quarter of 20...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US92556V1061
Viatris Inc
VTRS
LISTED
NASDAQ
Viatris Announces Quarterly Dividend
News Preview
PITTSBURGH, Nov. 4, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that on November 3, 2025, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The dividend is payable on December 15, 2025, to shareholders...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US69608A1088
Palantir Technologies, Inc.
PLTR
LISTED
NASDAQ
Dubai Holding and Palantir launch Aither: A joint venture to lead AI transformation
News Preview
Dubai Holding, a diversified global investment company with investments in more than 30 countries, and Palantir Technologies, a global leader in operational artificial intelligence platforms, have announced a strategic agreement to establish a joint venture (JV) - Palantir’s first in the UAE - named Aither. The partnership formalises 18 months of...
Themefolio
Profiler
Peergroup
© PR Newswire
04.11.2025
ISIN: US0758871091
Becton Dickinson and Co
BDX
LISTED
NYSE
BD Achieves Milestone in AGILITY Study of Revello™ Vascular Covered Stent for Treatment of Peripheral Artery Disease
News Preview
FRANKLIN LAKES, N.J., Nov. 4, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced full enrollment of the iliac artery patient cohort in its pivotal AGILITY Investigational Device Exemption (IDE) study, a prospective, multi-center study evalua...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US58933Y1055
Merck & Co Inc
MRK
LISTED
NYSE
Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the company has entered into an agreement to receive funds managed by Blackstone Life Sciences (“Blackstone”) for the development of sacituzumab tirumotecan (sac-TMT), an investigational antibody-drug conjugate (ADC) targeting trophoblast cell-surface ant...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US7170811035
Pfizer Inc
PFE
LISTED
NYSE
Pfizer Reports Solid Third-Quarter 2025 Results; Raises and Narrows 2025 EPS Guidance
News Preview
Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2025 and reaffirmed its 2025 Revenue guidance(1) while raising and narrowing guidance for Adjusted(2) diluted EPS.
EXECUTIVE COMMENTARY
Dr. Albert Bourla, Chairman and CEO of Pfizer:
“I am proud of Pfizer’s leadership as the first in our industry to reach an agreemen...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2025
ISIN: US58933Y1055
Merck & Co Inc
MRK
LISTED
NYSE
Merck Signs Agreement with Dr. Falk Pharma GmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal Antibody
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the company, through a subsidiary (Prometheus BioSciences), has reached an agreement with Dr. Falk Pharma GmbH (Falk) to discontinue an existing contract concerning co-development and co-commercialization rights in certain territories for MK-8690 (formerl...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
